These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Ziyadeh FN; Wolf G Curr Diabetes Rev; 2008 Feb; 4(1):39-45. PubMed ID: 18220694 [TBL] [Abstract][Full Text] [Related]
3. VEGF and angiopoietins in diabetic glomerulopathy: how far for a new treatment? Dei Cas A; Gnudi L Metabolism; 2012 Dec; 61(12):1666-73. PubMed ID: 22554833 [TBL] [Abstract][Full Text] [Related]
4. Transgenic overexpression of GLUT1 in mouse glomeruli produces renal disease resembling diabetic glomerulosclerosis. Wang Y; Heilig K; Saunders T; Minto A; Deb DK; Chang A; Brosius F; Monteiro C; Heilig CW Am J Physiol Renal Physiol; 2010 Jul; 299(1):F99-F111. PubMed ID: 20375117 [TBL] [Abstract][Full Text] [Related]
5. Inducible overexpression of sFlt-1 in podocytes ameliorates glomerulopathy in diabetic mice. Ku CH; White KE; Dei Cas A; Hayward A; Webster Z; Bilous R; Marshall S; Viberti G; Gnudi L Diabetes; 2008 Oct; 57(10):2824-33. PubMed ID: 18647955 [TBL] [Abstract][Full Text] [Related]
6. Soluble Flt-1 gene therapy ameliorates albuminuria but accelerates tubulointerstitial injury in diabetic mice. Kosugi T; Nakayama T; Li Q; Chiodo VA; Zhang L; Campbell-Thompson M; Grant M; Croker BP; Nakagawa T Am J Physiol Renal Physiol; 2010 Mar; 298(3):F609-16. PubMed ID: 20015944 [TBL] [Abstract][Full Text] [Related]
7. Quantitave and qualitative changes in vascular endothelial growth factor gene expression in glomeruli of patients with type 2 diabetes. Bortoloso E; Del Prete D; Dalla Vestra M; Gambaro G; Saller A; Antonucci F; Baggio B; Anglani F; Fioretto P Eur J Endocrinol; 2004 Jun; 150(6):799-807. PubMed ID: 15191350 [TBL] [Abstract][Full Text] [Related]
8. Angiopoietins and diabetic nephropathy. Gnudi L Diabetologia; 2016 Aug; 59(8):1616-20. PubMed ID: 27207083 [TBL] [Abstract][Full Text] [Related]
9. Cellular and molecular aspects of diabetic nephropathy; the role of VEGF-A. Carranza K; Veron D; Cercado A; Bautista N; Pozo W; Tufro A; Veron D Nefrologia; 2015; 35(2):131-8. PubMed ID: 26300505 [TBL] [Abstract][Full Text] [Related]
10. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. Vriese AS; Tilton RG; Elger M; Stephan CC; Kriz W; Lameire NH J Am Soc Nephrol; 2001 May; 12(5):993-1000. PubMed ID: 11316858 [TBL] [Abstract][Full Text] [Related]
11. VEGF and the diabetic kidney: More than too much of a good thing. Majumder S; Advani A J Diabetes Complications; 2017 Jan; 31(1):273-279. PubMed ID: 27836681 [TBL] [Abstract][Full Text] [Related]
12. [The effects of VEGF-R inhibitor on podocytopathy of rats with type I diabetic nephropathy]. Wang S; Li Y; Huang YJ Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2011 Sep; 27(9):1003-6. PubMed ID: 21906476 [TBL] [Abstract][Full Text] [Related]
13. Effects on protein kinase C-beta inhibition on glomerular vascular endothelial growth factor expression and endothelial cells in advanced experimental diabetic nephropathy. Kelly DJ; Buck D; Cox AJ; Zhang Y; Gilbert RE Am J Physiol Renal Physiol; 2007 Aug; 293(2):F565-74. PubMed ID: 17522264 [TBL] [Abstract][Full Text] [Related]
14. Glomerular endothelial cell injury and cross talk in diabetic kidney disease. Fu J; Lee K; Chuang PY; Liu Z; He JC Am J Physiol Renal Physiol; 2015 Feb; 308(4):F287-97. PubMed ID: 25411387 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of vascular endothelial growth factor (VEGF) does not affect early renal changes in a rat model of lean type 2 diabetes. Schrijvers BF; De Vriese AS; Tilton RG; Van de Voorde J; Denner L; Lameire NH; Flyvbjerg A Horm Metab Res; 2005 Jan; 37(1):21-5. PubMed ID: 15702434 [TBL] [Abstract][Full Text] [Related]
17. p27(Kip1) Knockout mice are protected from diabetic nephropathy: evidence for p27(Kip1) haplotype insufficiency. Wolf G; Schanze A; Stahl RA; Shankland SJ; Amann K Kidney Int; 2005 Oct; 68(4):1583-9. PubMed ID: 16164635 [TBL] [Abstract][Full Text] [Related]
19. Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Flyvbjerg A; Dagnaes-Hansen F; De Vriese AS; Schrijvers BF; Tilton RG; Rasch R Diabetes; 2002 Oct; 51(10):3090-4. PubMed ID: 12351452 [TBL] [Abstract][Full Text] [Related]
20. The VEGF-A inhibitor sFLT-1 improves renal function by reducing endothelial activation and inflammation in a mouse model of type 1 diabetes. Bus P; Scharpfenecker M; Van Der Wilk P; Wolterbeek R; Bruijn JA; Baelde HJ Diabetologia; 2017 Sep; 60(9):1813-1821. PubMed ID: 28620823 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]